Health and Healthcare
Juno, the Last IPO of 2014, Enters the Market With a Bang
Published:
Last Updated:
Juno Therapeutics Inc. (NASDAQ: JUNO) debuted on the market Friday morning and has made a big splash. The pricing for the offering was $24 per share, outside of the original range of $21 to $23 per share, on a total of 9.25 million shares, with an overallotment option for an additional 1.39 million shares.
The underwriters for the offering are Morgan Stanley, J.P. Morgan, Leerink Partners and Goldman Sachs.
Juno is a biopharmaceutical company focused on re-engaging the body’s immune system to treat cancer. The company was originally founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine. It is developing cell-based cancer immunotherapies based on a chimeric antigen receptor (CAR) and high-affinity T-cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
In its research, Juno leverages CAR and TCR technologies to activate a patient’s own T cells so that they attack cancer cells. Through genetic engineering, a gene for a particular CAR or TCR construct is inserted into the T cell that enables it to better recognize cancer cells. The CAR technology directs T cells to recognize cancer cells based on the expression of specific proteins located on the cell surface, whereas TCR technology provides the T cells with a specific T-cell receptor to recognize protein fragments derived from either the surface or inside the cell.
ALSO READ: The 7 Best Investments of 2014
The following are most advanced product candidates in the company’s pipeline that leverage CAR technology:
Despite pricing at $24 per share, Juno entered the market at $39.00 per share. In the first half of the trading day, shares were up nearly 60% from the pricing, at $38.35, moving nearly 9 million shares. The range on the day — so far — was $36.10 to $39.50.
ALSO READ: 10 Dying and 10 Thriving U.S. Industries
Afinancial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.